Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**1-[ (2,6-Difluorophenyl) sulfonyl ] -4-[ (2,3-dihydro - 1 , 4 - benzodioxin - 6 - yl ) sulfonyl ] piperazine** is a synthetic small molecule belonging to the benzenesulfonamide class. It is referenced in chemical and pharmaceutical databases as an experimental compound and has been assigned the code name ML285. The compound features two sulfone groups attached to a piperazine core with difluoro-substituted phenylene and benzodioxin moieties. There is no evidence of clinical development or approved therapeutic use; its mechanism of action and biological targets are not described in public drug databases[1][2][7]. It appears primarily in research contexts as a chemical probe or screening hit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine.